Imbio PHA (4.0.0) vs Cardiologs Holter Platform
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your clinical workflow involves analyzing CT pulmonary angiogram (CTPA) scans and you require automated, AI-driven measurements of cardiac structures. This tool is ideal for rapidly assessing right ventricular dilation and aiding in the diagnosis and risk stratification of conditions like pulmonary embolism and hypertension.
View Imbio PHA (4.0.0) →Choose Cardiologs Holter Platform if…
Choose Cardiologs Holter Platform if your practice frequently performs Holter ECG monitoring and you need an efficient, AI-powered solution for arrhythmia detection and analysis. This cloud-based platform is best suited for streamlining the interpretation of various Holter devices, significantly reducing analysis time, and generating comprehensive reports for a wide range of arrhythmias.
View Cardiologs Holter Platform →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | Cardiologs Holter Platform |
|---|---|---|
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Cloud |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cardiologs Holter PlatformCardiologs Holter Platform offers significant usability advantages through its cloud-based, anytime-anywhere access and vendor-neutral compatibility with various Holter devices. It quantifiably reduces Holter analysis time by approximately 42% and provides an ergonomic interface for efficient workflow. While Imbio PHA integrates seamlessly with DICOM workflows, Cardiologs' direct impact on analysis efficiency and accessibility gives it an edge.
Clinical Value
Cardiologs Holter PlatformBoth tools are FDA-cleared and provide significant clinical value in their respective domains. However, Cardiologs Holter Platform demonstrates more quantifiable clinical outcomes, including detecting over 20 types of arrhythmias, reducing AF false positives by 10x, and increasing VT detection sensitivity by 29%. It also holds the distinction of being the first FDA-cleared AI solution for ECG analysis in 2017, backed by extensive peer-reviewed publications and a vast dataset of over 200 million recordings.
Pricing & Value
Cardiologs Holter PlatformCardiologs Holter Platform offers more transparency in its pricing model by explicitly stating 'Pay per ECG regardless the number of users' [JSON, 4, 7]. This provides a clearer understanding of the cost structure. Imbio PHA, in contrast, only states 'contact for pricing,' offering no specific details on its cost model [JSON].
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA offers superior enterprise readiness due to its flexible deployment options, including cloud, on-premise, or via partners, catering to a wider range of institutional IT infrastructures and data security preferences [JSON, 24]. While Cardiologs Holter Platform provides robust cloud security with ISO/IEC 27001 certification and EMR integration, Imbio's on-premise option is a significant advantage for organizations with strict data residency requirements [JSON, 5, 24].
Innovation
Cardiologs Holter PlatformBoth tools leverage AI, but Cardiologs Holter Platform demonstrates a stronger claim to pioneering innovation as the 'first FDA-cleared AI solution for ECG analysis' in 2017. Its use of deep learning technology trained on over 200 million recordings and exploration of DNN technology for ECG biomarkers and smartwatch data analysis highlights its forward-thinking approach. Imbio PHA's application of AI to CTPA is innovative, but Cardiologs' broader impact and pioneering status in its field give it an edge.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA provides more explicit and detailed information regarding its support channels, including phone and email contacts, an online case submission form, and clear mention of readily available user manuals and product documentation. While Cardiologs Holter Platform mentions technical support via its platform and general documentation, Imbio's comprehensive listing of support options and resources indicates a more robust and transparent support infrastructure.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | Cardiologs Holter Platform |
|---|---|---|
| Name | Imbio PHA (4.0.0) | Cardiologs Holter Platform |
| Company | Imbio | Philips France Commercial |
| Description | FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | AI-powered, cloud-based solution for fast and accurate Holter ECG analysis, designed to detect over 20 types of arrhythmias and streamline cardiac diagnostics for healthcare professionals. |
| Primary Use Case | Automated measurement of cardiac structures from CT pulmonary angiogram (CTPA) scans for pulmonary embolism and hypertension assessment. | Fast and accurate Holter ECG analysis for arrhythmia detection. |
| Key Features (Cardiac Measurements/Analysis) | Automated measurement of right and left ventricle diameters; Automated measurement of main pulmonary artery and aorta diameters; Calculates RV/LV and PA/Ao ratios. | AI-powered deep learning technology for ECG analysis; Detects over 20 types of arrhythmias. |
| Reporting | Generates annotated DICOM images; Provides summary reports in PDF format. | Generates easy-to-read, automatically enriched reports. |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and Cardiologs Holter Platform.